All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub spoke to Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?
Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?
Ruxolitinib is a JAK1/2 inhibitor used to reduce spleen size and improve constitutional symptoms before transplantation. In this video, Kröger details when allogeneic stem cell transplantation should be performed in patients with myelofibrosis who have received treatment with ruxolitinib, based on available data from clinical trials.
Post-transplant cyclophosphamide and ruxolitinib as GvHD prophylactic regimen in patients with primary or secondary myelofibrosis
In a study published in Acta Haematologica, Elena Vladislavovna Morozova and colleagues evaluated the combination of...
Editorial theme | The management of relapsed/refractory myelofibrosis: Part 3 – treatment options beyond JAK inhibition
There is an ongoing effort to develop novel approaches with different modes of action to fulfil an unmet need when Janus kinase...
Subscribe to get the best content related to MPN delivered to your inbox